NCT02207361.

Study name	Paclitaxel in Combination With Carboplatin Versus Paclitaxel Plus Epirubicin in Metastatic Breast Cancer
Methods	Randomised prospective clinical trial.
Participants	Participants with metastatic breast cancer.
Interventions	Paclitaxel + carboplatin vs paclitaxel + epirubicin.
Outcomes	Response (RECIST 1.1).
Starting date	December 2013
Contact information	Zhongsheng Tong,18622221181@163.com
Notes	Limited conference abstract results published. Emails sent to the principal investigator in 2019 requesting mTNBC specific results were not answered.